SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

TARA

Protara Therapeutics
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong durability and safety profile of TARA-002 in BCG-Naïve NMIBC could de-risk the program and support regulatory path. Focus on completion of BCG-Unresponsive cohort enrollment in 2H 2026 and initiation of ADVANCED-3. Trading on clinical data updates can be volatile; monitor for any financing needs as the company advances toward registrational trials.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.10
T+0 close · May 15, 2026 · via day close
Latest settled
−23.33%
T+60 · $3.91
Vs SPY
−27.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $5.10entry
  2. T+1 · 6mo ago −9.80%α −9.74% · $4.60
  3. T+5 · 6mo ago −3.53%α −4.49% · $4.92
  4. T+20 · 5mo ago −22.75%α −24.86% · $3.94
  5. T+60 · 3mo ago −23.33%α −27.85% · $3.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve NMIBC patients, showing a 72.4% complete response rate at any time, 67% at 6 months, and 55% at 12 months, with no Grade 3+ treatment-related adverse events. The company remains on track to initiate the registrational ADVANCED-3 trial in 2H 2026. These data support TARA-002's potential as a differentiated treatment in a large unmet need market.

Key Facts

  • 72.4% complete response (CR) rate at any time in BCG-Naïve NMIBC patients (21/29 evaluable).
  • 66.7% CR rate at 6 months and 55.0% CR rate at 12 months.
  • No Grade 3 or greater treatment-related adverse events; most TRAEs were Grade 1 and transient.
  • Registrational ADVANCED-3 trial planned to initiate in 2H 2026 in BCG-Naïve and potentially BCG-Exposed patients.
  • TARA-002 has FDA Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations for certain indications.

Financial Impact

No financial data provided; clinical catalyst only.

Risk Factors

  • Clinical trial risks: Phase 2 data may not replicate in larger registrational study.
  • Regulatory risks: FDA may require additional data or raise concerns.
  • Competitive landscape: existing and pipeline therapies for NMIBC could limit commercial potential.
  • Financing risk: Protara may need to raise capital to fund ADVANCED-3 and ongoing operations.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295716

Track record

13 reports on TARA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Viewing Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026